Besides, the number of firms against which such complaints were seen has also seen an increase.
As on September 30, 567 complaints were pending for a period of more than 60 days against 23 firms, including Oil & Natural Gas Corporation (ONGC), Glaxosmithkline Pharmaceuticals, Malanpur Steel and Steel Exchange India Ltd.
In August, a total of 541 investor complaints remained unresolved by 21 listed companies, latest data with Sebi's Online Complaints Redress System (SCORES) showed.
However, the number of investor complaints have dropped by nearly half compared to over 1,000 grievances that were pending almost a year ago.
As per Securities and Exchange Board of India directive, listed firms are required to resolve investor complaints within a stipulated time of receiving them failing which they would be liable for penal action.
The data includes those entities against whom more than ten complaints are pending for more than 60 days and excludes entities against whom enforcement action has been initiated by Sebi for non-redressal of investor grievances.
There were 102 investor grievances against state-owned firm ONGC, while 14 complaints remained unresolved by drug maker Glaxosmithkline Pharmaceuticals Ltd.
Other companies on the list include Jupiter Bioscience (23), Rolex Pharmaceuticals (21), Midfield Industries (20), Acropetal Technologies (19) and Steel Exchange India (19).
Among other entities regulated by Sebi, which has set up SCORES for fast-track resolution and monitoring of investor complaints, a total of 60 complaints were pending for over two months against two mutual funds houses and one registrar to an issue/share transfer agent (Karvy Computershare Private Ltd).
Sebi online complaint redressal system, SCORES, lists all entities functioning in the capital market, including listed companies, stock exchanges, merchant bankers and mutual funds.
SCORES, launched in June 2011, provides a centralised database of all complaints, online movement of complaints to the concerned listed companies, online upload of Action Taken Reports (ATRs) by the concerned companies. It also helps investors view, track and follow up the actions taken on their grievance.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
